Gyan Chandra

Array ( [id] => 18460483 [patent_doc_number] => 11684761 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-27 [patent_title] => Preparation comprising exanatide for delivery into a lumen of the intestinal tract [patent_app_type] => utility [patent_app_number] => 17/077813 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 53 [patent_no_of_words] => 23842 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17077813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052248 [patent_doc_number] => 20210261682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 17/071791 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22220 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18383419 [patent_doc_number] => 11654183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Methods comprising continuous administration of exenatide and co-administration of a drug [patent_app_type] => utility [patent_app_number] => 17/069521 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 8709 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17069521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036700 [patent_doc_number] => 20210253658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS [patent_app_type] => utility [patent_app_number] => 17/032706 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17032706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770824 [patent_doc_number] => 20230365623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => DERIVATISATION OF PEPTIDES AND PROTEINS [patent_app_type] => utility [patent_app_number] => 18/024631 [patent_app_country] => US [patent_app_date] => 2020-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666272 [patent_doc_number] => 11773150 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors [patent_app_type] => utility [patent_app_number] => 17/004395 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 19287 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17004395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441925 [patent_doc_number] => 20220062430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => Self Assembling Protein Nanoparticles as Carrier Molecules [patent_app_type] => utility [patent_app_number] => 17/002571 [patent_app_country] => US [patent_app_date] => 2020-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17002571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16569160 [patent_doc_number] => 20210008166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX [patent_app_type] => utility [patent_app_number] => 16/996635 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20331 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711941 [patent_doc_number] => 20210079088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/994464 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16994464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18133920 [patent_doc_number] => 11559569 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Use of ultrarapid acting insulin [patent_app_type] => utility [patent_app_number] => 16/994404 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 28 [patent_no_of_words] => 27519 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16994404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20645823 [patent_doc_number] => 12600758 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-14 [patent_title] => Interleukin-2 muteins for the expansion of T-regulatory cells [patent_app_type] => utility [patent_app_number] => 17/634685 [patent_app_country] => US [patent_app_date] => 2020-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15301 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16504832 [patent_doc_number] => 20200384088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => INSULIN CONTAINING PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/984990 [patent_app_country] => US [patent_app_date] => 2020-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16984990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17874383 [patent_doc_number] => 11446376 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => Methods for treating heart failure using glucagon receptor antagonistic antibodies [patent_app_type] => utility [patent_app_number] => 16/941290 [patent_app_country] => US [patent_app_date] => 2020-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 25647 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 393 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16941290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102434 [patent_doc_number] => 11542309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose [patent_app_type] => utility [patent_app_number] => 16/929342 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 22170 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398839 [patent_doc_number] => 20200339697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => Methods For Treating Obesity And Nonalcoholic Fatty Liver Disease Or Nonalcoholic Steatohepatitis Using Glucagon Receptor Antagonistic Antibodies [patent_app_type] => utility [patent_app_number] => 16/928441 [patent_app_country] => US [patent_app_date] => 2020-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16928441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16619861 [patent_doc_number] => 20210038514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1-AGONIST AND METHIONINE [patent_app_type] => utility [patent_app_number] => 16/921422 [patent_app_country] => US [patent_app_date] => 2020-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16921422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675527 [patent_doc_number] => 20230313132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => METHOD FOR INDUCING NEURONAL SYNAPSE FORMATION AND MICROBEADS USED IN SAID METHOD [patent_app_type] => utility [patent_app_number] => 17/624506 [patent_app_country] => US [patent_app_date] => 2020-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790598 [patent_doc_number] => 20220249689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => PROTEIN-ENCLOSING POLYMERIC MICELLE [patent_app_type] => utility [patent_app_number] => 17/623144 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 300 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17623144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19151383 [patent_doc_number] => 11976282 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-07 [patent_title] => GATA3 inhibitors for the promotion of subcutaneous fat deposition [patent_app_type] => utility [patent_app_number] => 16/909755 [patent_app_country] => US [patent_app_date] => 2020-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 8 [patent_no_of_words] => 7538 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511608 [patent_doc_number] => 20200390865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 16/893498 [patent_app_country] => US [patent_app_date] => 2020-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16893498 [rel_patent_id] =>[rel_patent_doc_number] =>)